Case File
efta-efta01039703DOJ Data Set 9OtherFrom: "Paul V. Morris" 4
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01039703
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: "Paul V. Morris" 4
To: Jeffrey Epstein <[email protected]>
Subject: CIO Weekly Letter: With earnings, it's "global first"
Date: Wed, 26 Jul 2017 17:31:54 +0000
PBIG logo
;CIO Weekly
With earnings, it's "global first"
Notwithstanding chatter about "America First," rarely have the
stars aligned so well for U.S. multinationals—or firms with a
global footprint and, therefore, global exposure. The one-two
combo from accelerating non-U.S. global growth in
conjunction with a weaker U.S. dollar makes for the perfect
earnings brew for a number of U.S. firms across a swath of
industries. It also marks a significant departure from the past
few years.
Learn more in the new Weekly Letter, With earnings, it's
"global first", and feel free to contact us to talk about how we
might put insights of this kind to work for you.
Sincerely,
The Morris Group
Private Wealth Manager
If you prefer not to receive future emails from
click here
Investing involves risk, including the possible loss of principal.
Read the latest Weekly Letter
The Morris Group
Private Wealth Manager
The investments or strategies presented do not take into account the investment objectives or financial needs of particular
investors. It is important that you consider this information in the context of your personal risk tolerance and investment goals
before making an investment decision.
Investments have varying degrees of risk. Some of the risks involved with equities include the possibility that the value of the
stocks may fluctuate in response to events specific to the companies or markets, as well as economic, political or social events in
the U.S. or abroad.
EFTA01039703
Investments in foreign securities involve special risks, including foreign currency risk and the possibility of substantial volatility due
to adverse political, economic or other developments. These risks are magnified for investments made in emerging markets.
Investments focused in a certain industry may pose additional risks due to lack of diversification, industry volatility, economic
turmoil, susceptibility to economic, political or regulatory risks and other sector concentration risks.<
There are special risks associated with an investment in commodities, including market price fluctuations, regulatory changes,
interest rate changes, credit risk, economic changes and the impact of adverse political or financial factors.
Neither Merrill Lynch nor any of its affiliates or financial advisors provide legal, tax or accounting advice. You should consult your
legal and/or tax advisors before making any financial decisons.
Merrill Lynch makes available products and services offered by Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S")
and other subsidiaries of Bank of America Corporation ('BofA Corp.").
The Private Banking and Investment Group is a division of MLPF&S that offers a broad array of personalized wealth management
products and services. Both brokerage and investment advisory services (including financial planning) are offered by the group's
private wealth advisors through MLPF&S. The nature and degree of advice and assistance provided, the fees charged, and client
rights and Merrill Lynch's obligations will differ among these services. Investments involve risk, including the possible loss of
principal investment.
The banking, credit and trust services sold by the group's private wealth advisors are offered by licensed banks and trust
companies, including Bank of America, M., Member FDIC, and other affiliated banks.
Investment products:
Are Not FDIC Insured
Are Not Bank Guaranteed
May Lose Value
MLPF&S is a registered broker-dealer, registered investment adviser, Member SIPC and a wholly owned subsidiary of BofA Corp.
i 2017 Bank of America Corporation. All rights reserved. I ARBVKTQW 07/2017
EFTA01039704
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]SWIFT/BIC
ARBVKTQWRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.